In Leobendorf, Austria, Croma-Pharma celebrates a significant achievement in the first half of 2026 with the recent FDA approval of Obagi saypha® ChIQ™ in the United States. This injectable hyaluronic acid gel, developed by Croma-Pharma and brought to market by Obagi Medical, a Waldencast company, is now authorized for cheek augmentation and midface contour correction in adults aged 21 and over. This milestone marks a key development for the company in expanding its product portfolio.